Day: August 9, 2022

Alpharetta, Aug. 09, 2022 (GLOBE NEWSWIRE) — Mativ Holdings, Inc. (“Mativ” or the “Company”) (NYSE: MATV) reported earnings results for the three month and six month periods ending June 30, 2022. On July 6, 2022, SWM International, Inc. (“SWM”) and Neenah, Inc. (“Neenah”) completed a merger of equals (“the merger”) in which each SWM share was converted into one share of Mativ common stock and each share of Neenah was converted into 1.358 shares of Mativ common stock. Adjusted measures are reconciled to GAAP at the end of this release. Financial and operating comparisons are versus the prior year period unless stated otherwise. EPS figures are on a diluted basis unless stated otherwise. Figures may not sum to total due to rounding. Definitions: Advanced Materials &...

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights Advanced Plans to Diversify Portfolio and Invest in Innovative Rare Disease Opportunities Provides Guidance that Full-Year 2022 Adjusted EBITDA to be Between $100-105 Million Listing New Orange Book Patent Potentially Extends FIRDAPSE Patent Protection to 2037 Company to Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM EDT CORAL GABLES, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for...

Revised upwards 2022 Guidance for Pro Forma Adjusted EBITDA1,2,3 to $820 million to $840 million, representing a 5% increase over the prior guidance midpoint Completed $3.0 billion comprehensive, sustainability-linked refinancing, that retired all pre-existing debt facilities, together with a new, unsecured $1.25 billion 5-year revolving credit facility Issued its 2021 ESG Report highlighting the achievements of its predecessor entities, Altus and BCP Raptor Fully redeemed all Series A Preferred Units in July 2022, completing Kinetik’s overall capital structure simplification Reached Permian Highway Pipeline (“PHP”) expansion investment decision with expected in-service by November 1, 2023 Working with Enterprise Products on the announced Shin Oak expansion of up to 275 Mbbl/d of incremental capacity, with an expected completion in 2024HOUSTON...

Biosimulation software and services fuel second quarter growth PRINCETON, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance. Second Quarter Highlights:Revenue was $82.8 million, compared to $70.1 million in the second quarter of 2021, representing growth of 18% over the second quarter of 2021 on a reported basis and 21% at constant currency. Excluding Pinnacle 21, revenue was $75.8 million, representing growth of 8% over the second quarter of 2021 on a reported basis and 11% at constant currency. Net loss was $0.6 million, compared to net loss of $2.9 million in the second quarter of 2021, an increase of $2.3 million in income over the second quarter of 2021. Adjusted...

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer. “The highlight of another productive quarter was interim data from our ongoing Phase 1b/2a clinical trial of VTP-300 in patients with chronic hepatitis B,” said Bill Enright, Vaccitech’s CEO. “We saw not only a robust T Cell response, but also sustained HBsAg reductions with a single treatment – interim data points that, to our knowledge, have not been observed together...

SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Dolby Laboratories, Inc. (NYSE:DLB) today announced the company’s financial results for the third quarter of fiscal 2022. For the third quarter, Dolby reported total revenue of $289.6 million, compared to $286.8 million for the third quarter of fiscal 2021. “While the macroeconomic environment remains uncertain, we are focused on executing on our growth initiatives and remain confident in our long-term opportunity,” said Kevin Yeaman, President and CEO, Dolby Laboratories. “We continue to grow the adoption of Dolby Vision and Dolby Atmos across a broadening set of use cases, highlighted this quarter by important wins in mobile with Dolby Vision capture, and in music and automotive with Dolby Atmos.” Third quarter GAAP net income was $39.6 million, or...

EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Financial Results Our cash position as of June 30, 2022 was $24.5 million. Based on our current operating plan, we anticipate that our current cash and cash equivalents will fund our operations through the one-year period subsequent to the August 9, 2022 filing date of the Quarterly Report Form 10-Q. Research and development expenses for the three months ended June 30, 2022 totaled $2.7 million, compared to $3.9 million for the same period in 2021. General and administrative expense for the three months ended June 30, 2022 totaled $2.7 million, compared to $2.5 million for the same period...

PITTSBURGH, Aug. 09, 2022 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the second quarter ended June 30, 2022. Second Quarter Financial Highlights:Revenues of $67.9 million, increased 114.3% as compared to the second quarter of 2021 Net Income of $19.2 million, increased 511.7% as compared to the second quarter of 2021 Non-GAAP Adjusted EBITDA of $27.6 million, increased 435.0% as compared to the second quarter of 2021 RNG production of 1.5 million MMBtu, increased 3.7% as compared to the second quarter of 2021Montauk’s second quarter revenue reflects an increase in the number of Renewable Identification Numbers (“RINs”)...

Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2022. Second Quarter HighlightsReported record quarterly revenue of $5.2 million, a 52% year-over-year increase; Partner PTC Therapeutics received a positive opinion for its gene therapy treatment Upstaza™. from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Upstaza, which was granted full marketing authorization by the European Commission in July 2022, will be administered with the Company’s SmartFlow® Neuro Cannula; Increased biologics and drug delivery...

TORONTO and GATINEAU, Quebec, Aug. 09, 2022 (GLOBE NEWSWIRE) — Converge Technology Solutions Corp. (“Converge” or “the Company”) (TSX:CTS) (FSE:0ZB) (OTCQX:CTSDF) is pleased to provide its financial results for the three and six months ended June 30, 2022. All figures are in Canadian dollars unless otherwise stated. Financial SummaryIn $000s except per share amountsQ2 2022Q2 2021 Growth %H1 2022H1 2021 Growth %Gross revenues   729,678     452,120   61 %   1,403,607     860,220   63 %Net revenues   596,656     345,307   73 %   1,146,693     655,509   75 %Gross profit (GP)   133,152     78,244   70 %   242,196     146,040   66 %Gross profit (GP) %   22.3 %   22.7 %     21.1 %   22.3 %  Adjusted EBITDA   39,188     21,720   80 %   68,837     40,488   70 %Adjusted EBITDA as a % of GP   29.4 %   27.8 %     28.4 %   27.7 %  Adjusted...